Aarey Drugs & Pharmaceuticals (BOM:524412) EBIT: ₹104 Mil (TTM As of Mar. 2026)


BOM:524412 Aarey Drugs & Pharmaceuticals Ltd BOM:524412
60 GF Score
Price ₹87.88
GF Value ₹58.28
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Aarey Drugs & Pharmaceuticals EBIT?

Aarey Drugs & Pharmaceuticals BOM:524412 -2.00% 60 EBIT is ₹104 Mil as of Mar. 2026. GuruFocus rates BOM:524412 with a GF Score™ of 60/100 and a GF Value™ of ₹58.28 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Aarey Drugs & Pharmaceuticals's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was ₹31 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹104 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Aarey Drugs & Pharmaceuticals's annualized ROC % for the quarter that ended in Mar. 2026 was 6.63%. Aarey Drugs & Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 7.27%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Aarey Drugs & Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 3.52%.

Aarey Drugs & Pharmaceuticals  (BOM:524412) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Aarey Drugs & Pharmaceuticals's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=139.764 * ( 1 - 0% )/( (0 + 2106.672)/ 1 )
=139.764/2106.672
=6.63 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=0 - 0 - ( 0 - max(0, 0 - 0+0))
=0

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2972.467 - 831.815 - ( 33.98 - max(0, 1450.766 - 2629.422+33.98))
=2106.672

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Aarey Drugs & Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=122.592/( ( (0 + max(0, 0)) + (257.784 + max(1428.507, 0)) )/ 1 )
=122.592/( ( 0 + 1686.291 )/ 1 )
=122.592/1686.291
=7.27 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0) - (0 + 0 + 0)
=0

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1296.547 + 415.362 + 677.488) - (831.815 + 0 + 129.075)
=1428.507

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Aarey Drugs & Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=104.158/2957.412
=3.52 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aarey Drugs & Pharmaceuticals EBIT Related Terms

Aarey Drugs & Pharmaceuticals EBIT Historical Data

* Premium members only.

The historical data trend for Aarey Drugs & Pharmaceuticals's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aarey Drugs & Pharmaceuticals EBIT Chart

Aarey Drugs & Pharmaceuticals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 119.49 86.20 96.53 107.66 104.16

Aarey Drugs & Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 29.25 27.66 27.42 18.43 30.65

BOM:524412 vs ZTS, UTHR: EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Aarey Drugs & Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aarey Drugs & Pharmaceuticals EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aarey Drugs & Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Aarey Drugs & Pharmaceuticals's EV-to-EBIT falls into.


BOM:524412
60GF Score
Aarey Drugs & Pharmaceuticals Ltd BOM:524412
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aarey Drugs & Pharmaceuticals EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹104 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of ₹104 Mil mean?
Aarey Drugs & Pharmaceuticals (BOM:524412) has a EBIT of ₹104 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Aarey Drugs & Pharmaceuticals.
Is Aarey Drugs & Pharmaceuticals' EBIT too high?
Aarey Drugs & Pharmaceuticals' current EBIT is ₹104 Mil. Overall, Aarey Drugs & Pharmaceuticals has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aarey Drugs & Pharmaceuticals' EBIT compare to ZTS and UTHR?
Aarey Drugs & Pharmaceuticals' EBIT of ₹104 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Aarey Drugs & Pharmaceuticals. Aarey Drugs & Pharmaceuticals's current EBIT is ₹104 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aarey Drugs & Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Aarey Drugs & Pharmaceuticals (BOM:524412) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹58.28, compared to a current price of ₹87.88 — trading 50.8% above its estimated fair value. The current EBIT is ₹104 Mil. Aarey Drugs & Pharmaceuticals' overall GF Score™ is 60/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Aarey Drugs & Pharmaceuticals (BOM:524412), the current EBIT is ₹104 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Aarey Drugs & Pharmaceuticals (BOM:524412) Overvalued in 2026?

Based on GuruFocus' analysis, Aarey Drugs & Pharmaceuticals stock appears to be overvalued. The current stock price of ₹87.88 is trading 50.8% above its estimated GF Value™ of ₹58.28. GuruFocus considers Aarey Drugs & Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for BOM:524412:

  • EBIT: ₹104 Mil
  • GF Value™: ₹58.28 vs. price of ₹87.88 (50.8% above fair value)
  • GF Score™: 60/100 with 4 warning signs

No single metric tells the full story. See the BOM:524412 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Aarey Drugs & Pharmaceuticals Business Description

Other Exchanges AAREYDRUGS:India
Address 340/348, Narshi Natha Street, 107, Sahakar Bhavan, Masjid Bunder, Mumbai, MH, IND, 400 009
Aarey Drugs & Pharmaceuticals Ltd is engaged in bulk drug manufacturing and offers products for industrial applications. The company manufactures active pharmaceutical ingredients, intermediates, and specialty chemicals. It is also involved in the trading of industrial solvents and chemicals. The products offered by the company include N-Methyl urea, Dimethyl urea, Mefenamic acid, Metformin, Doxaphylline, and BMD among others. The company principally carries out its business operations in India.
60GF Score

Get the complete analysis for BOM:524412

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹87.88
Price
₹58.28
GF Value